---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-26-000029"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:09:42.388671+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct

## Summary
- Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).
- FY 2025 revenue $33.6M (+20% YoY); net loss $47.1M ($1.05/share).
- FY 2026 guidance: revenue $37-41M, 30-38 system placements, gross margin ~20%.
- Samsung Biologics placed multi-system Growth Direct order in Q1 2026, following Amgen's Q4 2025 multi-system order.
- Cash position $39M; $25M unused under Trinity Capital debt facility.

## SEC filing metadata
- accession: 0001380106-26-000029
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000029/0001380106-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000029/rpid-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-26-000029
- JSON: https://secwatch.observer/filing/0001380106-26-000029.json
- Plain text: https://secwatch.observer/filing/0001380106-26-000029.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported full year 2025 results: revenue $33.6 million, net income $47.1 million, EPS $1.05.
  - Period: full year 2025
  - Revenue: $33.6 million
  - Net income: $47.1 million
  - EPS: $1.05
  - Result: reported results
  source text: Total revenue for the full year was $33.6 million in 2025, compared to $28.1 million in 2024, representing an increase of 20%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000029/0001380106-26-000029-index.htm
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported fourth quarter of 2025 results: revenue $11.3 million, net income $12.5 million, EPS $0.28.
  - Period: fourth quarter of 2025
  - Revenue: $11.3 million
  - Net income: $12.5 million
  - EPS: $0.28
  - Result: reported results
  source text: Total revenue for the fourth quarter of 2025 was $11.3 million, compared to $8.2 million in the fourth quarter of 2024, representing an increase of 37%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000029/0001380106-26-000029-index.htm
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported full year 2026 results: revenue $37.0 million to $41.0 million. Guidance initiated.
  - Period: full year 2026
  - Revenue: $37.0 million to $41.0 million
  - Guidance: initiated
  - Result: guidance update
  source text: For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements and gross margins of approximately 20%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000029/0001380106-26-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.